Main Article Content
Rituximab is a chimeric IgG1 immunoglobulin that attacks B cells' CD20 molecules. Its efficiency in the treatment of B cell malignant proliferative illness has been proven since 1997. Rituximab is also used to treat autoimmune illnesses involving B cells, such as autoimmune hemolytic anaemia, autoimmune thrombocytopenia, rheumatoid arthritis (RA), Sjogren's syndrome (SS), and systemic lupus erythematosus (SLE) (SLE). A 19-year-old female patient was admitted to the hospital with complaints of painful raw lesions all over the body for 6 months, burning sensation of eyes with redness, fever for 10 days. On Day 4 of admission, the patient was started on Injection Rituximab, and the patient had variations in ECG observed, complaint of fever, associated with chills, tachycardia and insomnia, observed on the very first day of use. Each form of HSR has its own set of characteristics, as well as its own course and management. In terms of a tailored and exact approach, the new proposed classification appears to have clinical implications. Skin tests are the first stage in the diagnostic process, and if they are negative, DPT should be performed if appropriate settings are available. As a result, the desensitisation strategy requires more awareness and acceptance.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.